Given the importance of CTLA-4-expressing Tregs in maintaining immune homeostasis in the GIT, it is not surprising that therapeutic administration of CTLA-4-targeted MAbs in particular would predispose to development of enterocolitis. Here, CTLA4 is linked to enterocolitis.